MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Home・Aandelen Lijst・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Gesloten

SectorGezondheidszorg

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	-0.05% downside

Nieuwssentiment

By Acuity

50%

157 / 374 Rangschikking in Healthcare

Mirati Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

31 dec 2025, 22:20 UTC

Belangrijke Marktbewegers

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31 dec 2025, 17:31 UTC

Belangrijke Marktbewegers

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31 dec 2025, 16:30 UTC

Belangrijke Marktbewegers

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31 dec 2025, 15:19 UTC

Belangrijke Marktbewegers

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31 dec 2025, 15:17 UTC

Belangrijke Marktbewegers

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31 dec 2025, 14:37 UTC

Belangrijke Marktbewegers

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

31 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

31 dec 2025, 21:13 UTC

Acquisities, Fusies, Overnames

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31 dec 2025, 20:40 UTC

Marktinformatie

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31 dec 2025, 20:22 UTC

Marktinformatie

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31 dec 2025, 19:50 UTC

Marktinformatie

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31 dec 2025, 19:31 UTC

Marktinformatie

Precious Metals Cap Off Record Runs -- Market Talk

31 dec 2025, 18:50 UTC

Marktinformatie

Global Equities Roundup: Market Talk

31 dec 2025, 18:50 UTC

Marktinformatie

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31 dec 2025, 17:17 UTC

Marktinformatie

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31 dec 2025, 17:16 UTC

Belangrijke Marktbewegers

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31 dec 2025, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

31 dec 2025, 17:00 UTC

Acquisities, Fusies, Overnames

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31 dec 2025, 15:57 UTC

Acquisities, Fusies, Overnames

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31 dec 2025, 15:54 UTC

Marktinformatie

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31 dec 2025, 15:02 UTC

Belangrijke Marktbewegers

Nike Shares Rise After CEO Hill Buys $1M of Shares

31 dec 2025, 14:40 UTC

Acquisities, Fusies, Overnames

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31 dec 2025, 14:20 UTC

Marktinformatie

Crude Futures On Track to End the Year With Losses -- Market Talk

31 dec 2025, 13:46 UTC

Marktinformatie

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

31 dec 2025, 13:01 UTC

Winsten

Acquisities, Fusies, Overnames

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

31 dec 2025, 11:10 UTC

Marktinformatie

Copper Remains in Touching Distance of Record Highs -- Market Talk

31 dec 2025, 10:46 UTC

Marktinformatie

Euro on Track For Strong Annual Performance -- Market Talk

31 dec 2025, 10:25 UTC

Marktinformatie

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

31 dec 2025, 10:23 UTC

Marktinformatie

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

31 dec 2025, 09:33 UTC

Marktinformatie

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Peer Vergelijking

Prijswijziging

Mirati Therapeutics Inc Prognose

Koersdoel

By TipRanks

-0.05% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 58.67 USD -0.05%

Hoogste 59 USD

Laagste 58 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Mirati Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Mirati Therapeutics Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

157 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

EBITDA

Operationele winst

Over Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.